GSK Hopes to Lead New Class of Immunotherapies with Merck KGaA Collaboration
By Michelle Liu
Pharma Deals Review: Vol 2019 Issue 2 (Table of Contents)
Published: 8 Feb-2019
DOI: 10.3833/pdr.v2019.i2.2403 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
GlaxoSmithKline (GSK) has announced a collaboration with Merck KGaA for the co-development and co-commercialisation of M7824 (bintrafusp alfa), a fusion protein immunotherapy agent that targets two pathways commonly used by cancer cells – transforming growth factor-β (TGF-β) trap and an anti-programmed cell death ligand-1 (PD-L1)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS